Monte Rosa Therapeutics, Inc. Proceeds from Sale and Maturity of Marketable Securities
Monte Rosa Therapeutics, Inc. (GLUE) reported Proceeds from Sale and Maturity of Marketable Securities of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-20.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2025-03-20
- Monte Rosa Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2024-12-31 was $0.00.
- Monte Rosa Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2024-09-30 was $0.00.
- Monte Rosa Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2024-06-30 was $0.00.
- Monte Rosa Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- Monte Rosa Therapeutics, Inc. proceeds from sale and maturity of marketable securities for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Monte Rosa Therapeutics, Inc. proceeds from sale and maturity of marketable securities for fiscal 2023 was $45.63M.
- Monte Rosa Therapeutics, Inc. proceeds from sale and maturity of marketable securities for fiscal 2022 was $0.00.
- Monte Rosa Therapeutics, Inc. proceeds from sale and maturity of marketable securities for fiscal 2021 was $0.00.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 6 month as first filed | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 9 month as first filed | Proceeds from Sale and Maturity of Marketable Securities 12 month | Proceeds from Sale and Maturity of Marketable Securities 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $0.00 derived: sum of 2 quarters · filed 2025-03-20 | $0.00 derived: sum of 3 quarters · filed 2025-03-20 | $0.00 10-K · filed 2025-03-20 | |||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | $0.00 derived: sum of 4 quarters · filed 2025-03-20 | |||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | $0.00 derived: sum of 3 quarters · filed 2025-03-20 | $0.00 derived: sum of 4 quarters · filed 2025-03-20 | |||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 | $0.00 derived: sum of 2 quarters · filed 2025-03-20 | $0.00 derived: sum of 3 quarters · filed 2025-03-20 | $0.00 derived: sum of 4 quarters · filed 2025-03-20 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $0.00 derived: sum of 2 quarters · filed 2025-03-20 | $0.00 derived: sum of 3 quarters · filed 2025-03-20 | $45.63M 10-K · filed 2025-03-20 | |||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $45.63M 10-Q · filed 2024-11-07 | $45.63M derived: sum of 4 quarters · filed 2024-11-07 | |||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $45.63M 10-Q · filed 2024-08-08 | $45.63M derived: sum of 3 quarters · filed 2024-08-08 | $45.63M derived: sum of 4 quarters · filed 2024-08-08 | |||
| 2023-03-31 | $45.63M 10-Q · filed 2024-05-09 | $45.63M derived: sum of 2 quarters · filed 2024-05-09 | $45.63M derived: sum of 3 quarters · filed 2024-05-09 | $45.63M derived: sum of 4 quarters · filed 2024-05-09 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $0.00 derived: sum of 2 quarters · filed 2024-03-14 | $0.00 derived: sum of 3 quarters · filed 2024-03-14 | $0.00 10-K · filed 2024-03-14 | $178.00M 10-K · filed 2023-03-16 | ||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | $130.30M 10-Q · filed 2022-11-10 | $0.00 derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | $40.00M 10-Q · filed 2022-08-11 | $0.00 derived: sum of 3 quarters · filed 2023-08-10 | |||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | $0.00 derived: sum of 2 quarters · filed 2023-05-11 | |||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $0.00 10-K · filed 2023-03-16 | |||||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |